Cardlytics, Inc. (NASDAQ:CDLX) CEO Sells $23,232.44 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) CEO Amit Gupta sold 7,543 shares of Cardlytics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.08, for a total transaction of $23,232.44. Following the transaction, the chief executive officer now owns 157,376 shares of the company’s stock, valued at approximately $484,718.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Amit Gupta also recently made the following trade(s):

• On Wednesday, July 24th, Amit Gupta sold 22,699 shares of Cardlytics stock. The stock was sold at an average price of $8.66, for a total transaction of $196,573.34.

Cardlytics Stock Up 7.5 %

Shares of Cardlytics stock opened at $3.29 on Friday. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01. The firm has a market cap of $160.50 million, a P/E ratio of -0.74 and a beta of 1.67. Cardlytics, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $20.52. The business has a 50-day moving average price of $4.24 and a 200 day moving average price of $8.41.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.12. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The firm had revenue of $69.64 million during the quarter, compared to analyst estimates of $75.39 million. During the same period in the previous year, the company earned ($0.57) earnings per share. Cardlytics’s quarterly revenue was down 9.2% on a year-over-year basis. On average, sell-side analysts forecast that Cardlytics, Inc. will post -1.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quadrature Capital Ltd acquired a new position in shares of Cardlytics during the first quarter worth approximately $1,906,000. General Equity Holdings LP boosted its holdings in shares of Cardlytics by 31.0% in the fourth quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock worth $5,748,000 after buying an additional 147,843 shares during the period. Vanguard Group Inc. boosted its stake in Cardlytics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after purchasing an additional 57,805 shares during the period. Renaissance Technologies LLC boosted its position in shares of Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after buying an additional 307,800 shares during the period. Finally, Clear Street Markets LLC acquired a new stake in Cardlytics during the 4th quarter worth about $199,000. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on CDLX shares. Northland Capmk lowered shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Needham & Company LLC lowered Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Craig Hallum lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Lake Street Capital lowered Cardlytics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $18.00 to $5.00 in a research report on Thursday, August 8th. Finally, Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $7.00 to $5.00 in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $7.50.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.